You just read:

New Study of More Than 1,000 Dialysis Patients Reveals Significant Opportunity for Improvement of Hyperphosphatemia and Highlights the Potential for Amgen's Parsabiv

News provided by

Spherix Global Insights

Aug 03, 2017, 04:00 ET